Clinical Trial: SIMBA in Irritable Bowel Syndrome (IBS)

U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07882953) titled 'SIMBA in Irritable Bowel Syndrome (IBS)' on Oct. 06.

Brief Summary: This study is intended to characterize longitudinal changes in the small intestinal microbiome following rifaximin treatment in participants with Irritable Bowel Syndrome (IBS) over a 12 week period.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Irritable Bowel Syndrome (IBS) Microbiome

Intervention: DRUG: Rifaximin (drug)

Open label

DEVICE: fluid biopsy capsule

Collection of a fluid biopsy from the small intestine via ingestible capsule

Recruitment Status: NOT_YET_RECRUITING

Sponsor: University of Calgary

Disclaimer: Curated by HT S...